To assess changes in antidiabetes medication class prescriptions over time among patients with diabetic kidney disease (DKD), characteristics of patients prescribed these medications, and prescribers’ specialty.

We conducted a cohort study design using insurance claims data between 2013 and the first quarter of 2020 (2020Q1). Included are adult patients with DKD who initiated a new antidiabetes medication between 2013 and 2020Q1 (N = 160,489 patients). The primary outcome is the yearly and quarterly percent of medication initiation for each antidiabetes medication class over all antidiabetes medication initiations.

For patients with DKD, sodium–glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP-1RA) initiations steadily increased between 2013 and 2020Q1. Internists and endocrinologists were the most frequent prescriber specialties. Patients <65 years of age had a larger percentage of all initiations that were SGLT2i or GLP-1RA, 16% and 23%, respectively, in 2019, and patients >75 years of age had a smaller percentage of all initiations that were SGLT2i or GLP-1RA, 11% and 13%, in 2019.

For patients with DKD, SGLT2i and GLP-1RA prescriptions have increased over time, likely reflecting evolving prescribing patterns in response to the results of recent clinical trials and new clinical guidelines.

旨在评估糖尿病肾病 (DKD) 患者抗糖尿病药物类别处方随时间的变化、处方这些药物的患者特征以及处方者的专业。

我们利用 2013 年至 2020 年第一季度（2020Q1）的保险理赔数据进行了队列研究设计。其中包括 2013 年至 2020 年第一季度期间开始使用新的抗糖尿病药物的成年 DKD 患者（ N = 160,489 名患者）。主要结果是每年和每季度每种抗糖尿病药物开始用药占所有抗糖尿病药物开始用药的百分比。

对于 DKD 患者，钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 和胰高血糖素样肽 1 受体激动剂 (GLP-1RA) 的起始治疗在 2013 年至 2020 年第一季度期间稳步增加。内科医生和内分泌科医生是最常开处方的专业。 2019 年，<65 id=27>75 岁的患者在所有起始治疗中使用 SGLT2i 或 GLP-1RA 的比例较小，分别为 11% 和 13%。

对于 DKD 患者，SGLT2i 和 GLP-1RA 处方随着时间的推移而增加，可能反映了根据最近的临床试验结果和新的临床指南不断变化的处方模式。